ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 572,11
-0,79%
Dow Jones
40 211,72
0,53%
DAX
18 498,66
-0,55%
Brent Oil
83,10
-1,47%
Bitcoin
63 738,63
-1,72%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) Actualités

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateHeureSourceTitreSymboleSociété
17/06/201613h00GlobeNewswire Inc.First Patient Enrolled in Summit’s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMDNASDAQ:SMMTSummit Therapeutics Inc
16/06/201613h00GlobeNewswire Inc.Summit Therapeutics to Present at JMP Securities Life Sciences ConferenceNASDAQ:SMMTSummit Therapeutics Inc
08/06/201613h00GlobeNewswire Inc.Summit Therapeutics to Host Utrophin R&D Day 15 June 2016NASDAQ:SMMTSummit Therapeutics Inc
06/06/201612h01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SMMTSummit Therapeutics Inc
02/06/201622h36Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
02/06/201613h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational ProgressNASDAQ:SMMTSummit Therapeutics Inc
31/05/201613h00GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016NASDAQ:SMMTSummit Therapeutics Inc
26/05/201622h17Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3/a)NASDAQ:SMMTSummit Therapeutics Inc
25/05/201615h44Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:SMMTSummit Therapeutics Inc
23/05/201613h00GlobeNewswire Inc.Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM...NASDAQ:SMMTSummit Therapeutics Inc
12/05/201612h06Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:SMMTSummit Therapeutics Inc
12/05/201612h06Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:SMMTSummit Therapeutics Inc
10/05/201613h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016NASDAQ:SMMTSummit Therapeutics Inc
06/05/201613h00GlobeNewswire Inc.Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016NASDAQ:SMMTSummit Therapeutics Inc
28/04/201617h46GlobeNewswire Inc.Summit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the...NASDAQ:SMMTSummit Therapeutics Inc
28/04/201613h00GlobeNewswire Inc.Summit Announces Further US Patent Granted for CDI Antibiotic RidinilazoleNASDAQ:SMMTSummit Therapeutics Inc
11/04/201613h00GlobeNewswire Inc.Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infe...NASDAQ:SMMTSummit Therapeutics Inc
06/04/201613h00GlobeNewswire Inc.Summit Therapeutics to Present at 15th Annual Needham Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
30/03/201613h00GlobeNewswire Inc.Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients W...NASDAQ:SMMTSummit Therapeutics Inc
29/03/201615h25GlobeNewswire Inc.Summit to Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole’s Statistical Superiority Over Vancomycin ...NASDAQ:SMMTSummit Therapeutics Inc
15/03/201612h00GlobeNewswire Inc.Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMDNASDAQ:SMMTSummit Therapeutics Inc
10/03/201601h46GlobeNewswire Inc.Summit Announces Ridinilazole Preserves the Gut Microbiome of Patients With C. difficile Infection in Phase 2 TrialNASDAQ:SMMTSummit Therapeutics Inc
10/03/201601h46GlobeNewswire Inc.Summit Therapeutics Supports Ninth Annual Rare Disease DayNASDAQ:SMMTSummit Therapeutics Inc
10/03/201601h46GlobeNewswire Inc.Summit Therapeutics Announces Publication of Preclinical Data Showing Ridinilazole Outperformed Standard of Care in Reducing ...NASDAQ:SMMTSummit Therapeutics Inc
17/02/201613h00GlobeNewswire Inc.Summit Therapeutics to Participate in SunTrust Robinson Humphrey’s 2016 Orphan Drug DayNASDAQ:SMMTSummit Therapeutics Inc
16/02/201619h20Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SMMTSummit Therapeutics Inc
03/02/201613h00GlobeNewswire Inc.Summit Therapeutics to Present at 18th Annual BIO CEO & Investor ConferenceNASDAQ:SMMTSummit Therapeutics Inc
21/01/201613h00GlobeNewswire Inc.Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients ...NASDAQ:SMMTSummit Therapeutics Inc
19/01/201613h00GlobeNewswire Inc.Summit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile InfectionNASDAQ:SMMTSummit Therapeutics Inc
17/12/201513h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2015 and Operational ProgressNASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Dernières Valeurs Consultées

NASDAQ
GAN
GAN
BIT
P23HW4
NLBNPIT23HW4 20991231 27...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés